63
Participants
Start Date
October 16, 2006
Primary Completion Date
March 20, 2007
Study Completion Date
March 20, 2007
GSK716155 subcutaneous injections
GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
GSK Investigational Site, Morrisville
GSK Investigational Site, Orlando
GSK Investigational Site, Miramar
GSK Investigational Site, San Antonio
GSK Investigational Site, Long Beach
GSK Investigational Site, Walnut Creek
Lead Sponsor
GlaxoSmithKline
INDUSTRY